Stanford Cancer Institute
Head and Neck

Relapsed or Metastatic

Treatment

Squamous Cell Carcinoma of Head and Neck

Lesions amenable to injection No curative TX option

ENT0055
Phase III Nivolumab in Combo w/ Ipilimumab vs. Cetuximab +Cisplatin/ Carboplatin +Fluorouracil in SCCHN
Pi: Colevas Bristol Myers-Squibb

ENT0064
Phase 1b Ad/ PNP-F-araAMP + Co-Admin of Fludarabine Phosphate in Recurrent Local Head & Neck Cancer
Pi: Colevas Stanford

Advanced Disease

Prior Chemo

ENT0052
Phase I/II IPH2201 And Cetuximab in recurrent or metastatic SCC of head and neck
Pi: Colevas Innate Pharm SA

ENT0064
Phase I Anti-CD27 Antibody(Varlitumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Refractory Solid Tumors
Pi: Sikic Cellnex Therapeutics

Nasopharyngeal Carcinoma

ENT0052
Phase III Gemcitabine & Carboplatin +/- Vируs specific Autologous CTL in Nasopharyngeal Carcinoma
Pi: Colevas Pending

Diagnostic

Ameloblastoma

ENT0043
A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma
Pi: Colevas Stanford

ENT0050
Ph 1 Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Pi: Rosenthal Stanford

ENT0065
Phase II Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic PI: Rosenthal Stanford

Supportive Care

Correlative

ENT0049
Phase I Cetuximab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic
Pi: Rosenthal Stanford

ENT0042
Phase III Hypochlorite(Modified Dakin's Solution) Tx in Prevention of Radiation Dermatitis in H&N CA
Pi: Hara Stanford

ENT0066
Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Pi: Colevas Stanford

KEY

Pending
Open for Enrollment
Optional Path
Extension Study
Immunotherapy
Observational Study
Enrollment on Hold

Please mark up a copy using black ink and fax changes to 725-9204